Marie Fidela R. Paraiso, MD

• Section Head, Center of Urogynecology and Reconstructive Pelvic Surgery,
• Co-Director, Female Pelvic Medicine and Reconstructive Surgery, Director of
• the Pelvic Floor Disorders Center, Lakewood Hospital
• Assistant Professor of
• Surgery, Department of Obstetrics and Gynecology, Obstetrics, Gynecology,
• and Women? Health Institute, Cleveland Clinic, Cleveland, Ohio

In particular medications 2 times a day buy generic mesalamine 800 mg line, it has been suggested that for patients with type 2 diabetes mellitus medicine used for adhd discount mesalamine 800 mg on-line, hypomagnesemia contributes to diabetic complications by affecting glucose transport and insulin secretion and utilization medications hypothyroidism purchase mesalamine with amex. Indeed symptoms gallbladder problems discount 800 mg mesalamine otc, it has been shown that oral magnesium supplementation in type 2 diabetic patients with hypomagnesemia improves insulin sensitivity and metabolic control medications known to cause nightmares purchase 800 mg mesalamine amex. Hypomagnesemia in patients with type 2 diabetes may be associated with impaired insulin and glucose utilization. Supplementation in hypomagnesemic diabetes patients increases insulin sensitivity and metabolic control, but its effect on clinical outcomes has yet to be elucidated. Evaluation of Therapeutic Outcomes In patients with acute, asymptomatic mild to moderate hypomagnesemia, serum magnesium concentrations should be obtained at least daily during their hospitalization. Patients being treated for symptomatic 771 severe hypomagnesemia should have their serum magnesium concentration monitored hourly until the serum concentration reaches 1. At that point, the serum magnesium concentration can be monitored every 6 to 12 hours for the next 24 hours while receiving magnesium supplementation. Once the magnesium concentration is stable in the normal range, a concentration can be obtained daily. It should be reiterated that it typically takes 3 to 5 days to fully replete total-body magnesium stores. Patients receiving oral magnesium-containing antacids or supplements should be asked regularly about the occurrence of diarrhea. In cases of mild, chronic magnesium loss, oral magnesium preparations can be used; however, the dose-limiting side effect is diarrhea. As long as the patient maintains a normal diet, the serum magnesium concentration typically stabilizes at approximately 2. Critically ill patients with multiorgan system failure receiving enteral or parenteral nutrition are also prone to develop hypermagnesemia. Finally, the parenteral treatment of eclampsia with magnesium sulfate can lead to hypermagnesemia. Nonpharmacologic Therapy There are currently no nonpharmacologic options for the management of hypermagnesemia. Pharmacologic Therapy There are three primary means of treating hypermagnesemia: (a) reduce magnesium intake, (b) enhance elimination of magnesium, and (c) antagonize the physiologic effects of magnesium. Oral calcium is not effective because of 772 its relatively poor bioavailability and slow onset of action. Supportive care with cardiac pacing, vasopressors, and mechanical ventilation can be necessary in life-threatening situations. In dialysis patients, their hemodialysis prescription should be changed to employ magnesium-free dialysate. Severe cases of hypermagnesemia can result in neurologic symptoms or cardiac dysrhythmias. At this time, there are no genetic, genomic, or pharmacokinetic factors that are used to personalize pharmacotherapy for the treatment of these electrolyte disorders. Close monitoring of the urine output and physical examination for signs of volume overload are important. Emergency hemodialysis will usually correct the hypermagnesemia within 4 hours and is a reasonable option for those who are currently receiving hemodialysis. To prevent further episodes of hypermagnesemia, the patient should receive dietary education regarding foods and beverages that contain large quantities of magnesium (Table 51-9). Potassium intake, stroke, and cardiovascular disease: A meta-analysis of prospective studies. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease. Stimulated active potassium secretion in a patient with colonic pseudoobstruction: A new mechanism of secretory diarrhea. New guidelines for potassium replacement in clinical practice: A contemporary review by the National Council on Potassium in Clinical Practice. Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Ion-exchange resin for the treatment of hyperkalemia: Are they safe and effective Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Hypomagnesaemia in patients hospitalised in internal medicine is associated with increased mortality. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetes subjects. The respiratory compensatory response to metabolic disturbances is initiated rapidly whereas the metabolic compensatory response to respiratory disturbances occurs more slowly. Metabolic acidosis and metabolic alkalosis are generated by a primary change in the serum bicarbonate concentration. In metabolic acidosis, bicarbonate is lost or a nonvolatile acid is gained, whereas metabolic alkalosis is characterized by a gain in bicarbonate or a loss of nonvolatile acid. Although respiratory compensation for a primary metabolic acidosis begins rapidly (within 15-30 minutes) it does not reach a steady state for 12 to 24 hours after the onset of metabolic acidosis. Primary therapy of most acid­base disorders must include treatment or removal of the underlying cause, not just correction of the pH and electrolyte disturbances. Potassium supplementation is always necessary for patients with chronic metabolic acidosis, as the bicarbonaturia resulting from alkali therapy increases renal potassium wasting. Effective treatment of the underlying cause of some organic acidoses (eg, ketoacidosis) can result in bicarbonate regeneration within hours thus mitigating the need for alkali therapy. Loss of gastric acid from vomiting or nasogastric suctioning may lead to hypochloremia and hyperbicarbonatemia and may often lead to a metabolic alkalosis. Aggressive diuretic therapy can produce a metabolic alkalosis, and the accompanying hypokalemia can be serious. Management of these disorders usually consists of treatment of the underlying cause of mineralocorticoid excess. In patients 2 In most cases of acute metabolic acidosis, such as following cardiopulmonary arrest, sodium bicarbonate therapy is not indicated and can be detrimental. This article reviews the mechanisms responsible for the maintenance of acid­base balance and the laboratory analyses that aid clinicians in their assessment of acid­base disorders. The pathophysiology of the four primary acid­ base disturbances is presented, evidence-based therapeutic options are reviewed, and management guidelines to optimize the outcome of patients with one of these disorders are presented. Given that medications are a frequent cause of acid­base abnormalities and that acid­ base abnormalities are often preventable, clinicians must anticipate drug-related problems to avoid or minimize the clinical consequences of acid­base disorders, and when necessary, design appropriate treatment regimens. The acidity of body fluids is quantified in terms of the hydrogen ion concentration. By convention, the degree of acidity is expressed as pH, or the negative logarithm (base 10) of the hydrogen ion concentration. The hydrogen ion concentration in blood may not be indicative of that in other body compartments. For example, the pH within cells, within the cerebrospinal fluid, or on the surface of bone can all be altered without causing an alteration in blood pH. Alterations in blood pH serve as the basis for the diagnosis of acid­base disorders. Because the dissociation of acid­base pairs is an equilibrium reaction, the relationship between hydrogen ion concentration or pH and the relative concentrations of the acid and base can be described mathematically in terms of the dissociation constant for the acid­base buffer pair. An acid­base pair is most efficient in functioning as a buffer at a pH close to its pK. Because the isohydric principle requires that all buffer systems remain in chemical equilibrium, the complex buffering of biologic fluids can be analyzed based on a single buffer pair. The carbonic acid/bicarbonate buffer system plays a unique role in acid­base homeostasis. In addition to being the most abundant extracellular buffer, the components of this buffer pair exist under dynamic regulation by the body. In addition, small amounts of acid and alkali are also presented to the body through the diet. Digestion of dietary substances and tissue metabolism also result in the production of nonvolatile acids. These acids are derived primarily from the sulfur-containing amino acids cysteine and methionine, as well as from ingested sulfur. In addition, phosphates are generated from the metabolism of proteins and phospholipids. Neutral substances such as glucose can also be incompletely metabolized to intermediates, such as lactic and pyruvic acid, and fatty acids can be incompletely metabolized to acetoacetic acid and -hydroxybutyric acid. These dietary and metabolic fixed acids are excreted primarily by the kidney to maintain acid­base homeostasis. Finally, over a period of day(s), the kidney will excrete the excess hydrogen ion and acid­base balance will return to normal. Bicarbonate represents the metabolic component because the kidney may alter its concentration by reabsorption, generating new bicarbonate, or altering elimination. Extracellular phosphate is present only in low concentrations, so its usefulness as a buffer is limited; however, as an intracellular buffer, phosphate is more useful. Calcium phosphate in bone is relatively inaccessible as a buffer, but prolonged metabolic acidosis will result in the release of phosphate from bone. Because the concentration of protein is much greater intracellularly than extracellularly, protein is much more important as an intracellular buffer. The carbonic acid dissociates the former hydrogen ion that can again be secreted into the tubular lumen, and bicarbonate that exits the cell across the basolateral membrane and enters the peritubular capillary. The pathophysiologic processes Renal Regulation 1 Bicarbonate is freely filtered at the glomerulus because it is a small ion. The bicarbonate load delivered to the nephron is approximately 4,500 mEq/day (mmol/day). To maintain acid­base balance, this entire filtered bicarbonate load must be reabsorbed. In the tubular lumen, filtered bicarbonate combines with hydrogen ion, secreted by the apical sodium ion (Na+)­H+-exchanger, to form carbonic acid. The carbonic acid dissociates to form hydrogen ions that can again be secreted into the tubular lumen, and bicarbonate that exits the cell across the basolateral membrane and enters the peritubular capillary. For each ammonium ion excreted in the urine, one bicarbonate ion is regenerated and returned to the circulation. The bicarbonate exits the cell across the basolateral membrane and enters the circulation. Bicarbonate exits the cell across the basolateral membrane and enters the peritubular capillary. In metabolic acid­base disorders, the primary disturbance is in the plasma bicarbonate concentration. Metabolic acidosis is characterized by a decrease in the plasma bicarbonate concentration whereas in metabolic alkalosis the plasma bicarbonate concentration is increased. Although the time course of the respiratory compensatory response to metabolic disturbances is rapid, the metabolic compensation for respiratory disturbances is slow. As a result, respiratory disturbances are characterized as acute (minutes to hours in duration), indicating that there has not been sufficient time for metabolic compensation, or chronic (days), indicating that sufficient time for metabolic compensation has elapsed. Arterial blood reflects how well the blood is being oxygenated by the lungs (an accurate measurement of PaO2), whereas venous blood reflects how much oxygen tissues are using. Arterial blood rather than venous blood should be used whenever possible because venous blood obtained from an extremity can provide misleading information. If metabolism in the extremity is altered by hypoperfusion, exercise, infection, or some other cause, the difference in the amount of dissolved oxygen between arterial and venous blood can be dramatic. The serum bicarbonate concentration is variable, depending on whether it is an acute disturbance (minimal increase in serum bicarbonate) or a chronic respiratory acidosis (substantial increase in serum bicarbonate). Although each measurement has a normal range (see Table 52-3), it is often easiest to consider the midpoint of each range as the normal value. Under normal circumstances, the pH difference between arterial and mixed venous blood is not clinically significant. However, the oxygenation difference between arterial and mixed venous blood is always substantial. This value is lower than the value of 12 mEq/L (mmol/L) cited in the literature in the past because of changes in the instrumentation for measurement of serum electrolytes. The metabolic acidosis observed in patients with kidney disease is initially hyperchloremic but can progress to an anion-gap acidosis as kidney disease progresses and sulfates, phosphates, and other anions accumulate. Hyperaldosteronism predisposes to the development of hyperkalemia, which results in further impairment of ammoniagenesis. Treatment to control the hyperkalemia is usually sufficient to reverse the metabolic acidosis, and mineralocorticoid replacement is frequently unnecessary. Patients with this defect have impaired tubular potassium secretion in addition to impaired urinary acidification (urine pH more than 5. Normally, more than 85% of filtered bicarbonate is reabsorbed in the proximal tubule. Defects in proximal tubular bicarbonate reabsorption result in increased delivery of bicarbonate to the distal nephron, which has a limited capacity for bicarbonate reabsorption. As a result, at a normal serum bicarbonate concentration, the filtered bicarbonate load is incompletely reabsorbed, and is lost in the urine. As the serum bicarbonate concentration decreases, the filtered load of bicarbonate is proportionately decreased. A new equilibrium is established in which the kidney is able to reabsorb the filtered bicarbonate load, albeit at a reduced serum bicarbonate concentration. These patients are able to acidify their urine in response to an acid load, but develop bicarbonaturia at a reduced serum bicarbonate concentration following bicarbonate loading. The impaired bicarbonate reabsorption results in salt wasting and secondary hyperaldosteronism. Hypokalemia, which can be severe, usually develops as a result of the hyperaldosteronism and bicarbonaturia.

Syndromes

• Feeling well and having energy in general
• Splints or orthotics to support joints and help improve their position; this is often needed for rheumatoid arthritis
• Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
• Removal of blood (phlebotomy)
• Fainting
• Hematoma (blood accumulating under the skin)
• A rectal exam may find tenderness on the right side of your rectum.

Monitoring of uterine activity along with intensive surveillance does not minimize risk medications causing hair loss generic mesalamine 800 mg line. Fetal fibronectin determinations and cervical ultrasound have not helped to prevent preterm labor but have been useful for their negative predictive value medications you can take while breastfeeding generic 400 mg mesalamine otc. The criteria for starting tocolysis are regular uterine contractions with cervical change symptoms 1dpo purchase mesalamine 400 mg line. Tocolytic therapy should not be used in cases of previability symptoms 6 year molars cheap mesalamine 800 mg without a prescription, intrauterine fetal demise medications not to take when pregnant 800 mg mesalamine buy visa, a lethal fetal anomaly, intrauterine infection, fetal distress, severe preeclampsia, vaginal bleeding, or maternal hemodynamic instability. All four therapies prolong pregnancy between 48 hours to 1 week; however, this prolongation is not associated with a statistically significant reduction in overall rates of respiratory distress syndrome, neonatal death, or preterm birth before 37 weeks of gestation. Relative to other agents, -agonists have a higher incidence of maternal side effects, including hyperkalemia, arrhythmias, hyperglycemia, hypotension, and pulmonary edema. Recommended terbutaline doses vary because its use as a tocolytic agent is off-label; a commonly used dose is 250 mcg subcutaneously which may be repeated in 15 to 30 minutes for inadequate response with a maximum of 500 mcg given in a 4-hour period. These findings should not affect the use of magnesium sulfate for neuroprotection. At toxic levels, hypotension, muscle paralysis, tetany, cardiac arrest, and respiratory depression may occur. Nifedipine is associated with fewer side effects than magnesium or -agonist therapy and decreases risk of delivery within 7 days compared to -agonists. However, a meta-analysis showed reduced neonatal morbidity with calcium channel blocker use. With the initial diagnosis of preterm labor, nifedipine loading doses range between 10 and 40 mg with subsequent dosing of 10 and 20 mg every 4 to 6 hours with dose adjustment based on patterns of preterm contractions. An increased rate of premature constriction of the ductus arteriosus has been noted in infants with indomethacin use after 32 weeks of gestation and with use exceeding 48 hours. Other Drug Therapies for Preterm Labor Prevention Infection is a potential cause of preterm labor. Antibiotics have been used, in addition to tocolytics and corticosteroids, to improve the outcome of preterm labor; however, a Cochrane review showed no reduction in the incidence of preterm delivery, respiratory distress syndrome, or neonatal sepsis but a trend toward increased neonatal mortality. Progesterone administration in the setting of prior preterm birth is based upon its effects to diminish cervical ripening (softening of the cervix necessary for cervical dilation before birth), reduce uterine wall contractility, and modulate inflammation. Use of intramuscular 17-hydroxyprogesterone weekly (250 mg) or vaginal progesterone suppositories (100 mg) starting between weeks 16 and 24 continued through week 36 in women with a previous spontaneous preterm birth is recommended. Results should be interpreted cautiously since the outcomes measured were secondary endpoints and analyzed through meta-analysis of studies, all of which used different antibiotic regimens. During the last few weeks of pregnancy, the cervix softens and thins to facilitate labor. This process is mediated by hormonal changes, including final mediation by prostaglandins E2 and F2, which increase collagenase activity in the cervix leading to thinning and dilation. Contraindications include placenta previa, oblique or transverse lie, pelvic structure abnormality, prolapsed umbilical cord, and active herpes. Concerns with induction of labor are ineffective labor and side effects, such as uterine hyperstimulation, that may adversely affect the infant and increase the likelihood of cesarean section. Scoring systems have been used to determine the likelihood of successful labor induction. Castor oil, hot baths, sexual intercourse, and nipple stimulation all have been suggested for labor induction. Use of a Foley catheter placed in an unfavorable cervix for ripening has been found as effective as prostaglandin E2. Cervidil contains 10 mg dinoprostone with a slower, more constant release of medication than the gel. Patients must be attached to a fetal heart rate monitor for the duration of Cervidil use and for 15 minutes after its removal. Intravaginal administration of 25 mcg misoprostol (oral tablets are split to obtain dose) given every 3 to 6 hours is at least as effective as other prostaglandin agents and results in a shorter time to delivery. The most commonly encountered side effects are uterine hyperstimulation and meconium-stained amniotic fluid. Use of misoprostol is contraindicated in women with a previous uterine scar because of its association with uterine rupture, a catastrophic medical event. Salvage ("rescue") treatment administered to women at risk of delivering within 7 days but who received a previous course of therapy is also supported by a Cochrane review. Risk of respiratory distress syndrome was lower with the administration of rescue steroids compared with placebo (risk ratio 0. The incidence of early-onset disease in neonates, although higher than in pregnant women, has declined steadily from 1. The consequences of neonatal infections include bacteremia, pneumonia, meningitis, and fatality in the newborn. All other pregnant women should have a vaginal/ rectal culture at 35 to 37 weeks of gestation. If a woman presents in labor and no screening information is available, antibiotics are given for fever greater than 100. Preliminary studies show that mifepristone, an antiprogesterone agent, compared with placebo results in a shorter time to delivery and fewer cesarean sections. Oxytocin is the most commonly used agent for labor induction after cervical ripening. By the end of pregnancy, the number of oxytocin receptors has increased by 300-fold. Oxytocin is effective in both low-dose (physiologic) and high-dose (pharmacologic) regimens. Epidural analgesia is associated with prolongation of the first and second stages of labor, higher numbers of instrumental deliveries and cesarean sections (for fetal distress), and maternal fever. Other complications include hypotension, nausea, vomiting, itching, and urinary retention. During the first phase of labor, women perceive visceral pain caused by uterine contractions. Risk factors include retained placenta, failure to progress during the second stage of labor, placenta previa, placenta accreta, lacerations, instrumental delivery, large for gestational age newborn, hypertensive disorders, labor induction, augmentation of labor with oxytocin, prior history, maternal obesity, and preeclampsia. After the exclusion of retained products of conception and cervical and vaginal lacerations, attention should be turned to the management of uterine atony if present. Methylergonovine, carboprost, misoprostol, and dinoprostone have all been used; less evidence is available for misoprostol and dinoprostone. If uterotonic drug therapies fail to control the bleeding, uterine artery embolization, intrauterine balloon catheters, or a variety of different surgical techniques can be used. Intradermal injections of sterile water in the sacral area provide short-term decreases in back pain during labor. Several randomized, controlled trials have shown that acupuncture decreases the need for analgesia, but more methodologically sound studies are needed. Combined spinal-epidural analgesia consists of injecting a single opioid bolus into the subarachnoid space to provide instant pain relief with additional use of a local anesthetic epidural; compared with traditional epidurals, combined spinal-epidural anesthesia has a slightly shorter mean time to onset of effective analgesia. Women should breastfeed exclusively for 6 months and continue until at least 12 months of age while other foods are introduced. Metoclopramide can be used if nonpharmacologic measures are ineffective because of its stimulation of prolactin secretion. Most drugs transfer into breast milk, but breastfeeding may be continued in most circumstances. Healthcare providers should encourage breastfeeding women who require medications to continue breastfeeding whenever possible. Passive diffusion is the primary mechanism for drug transfer into breast milk, but other drug-related factors influence drug transfer from maternal circulation into breast milk, including (a) degree of protein binding in maternal plasma, (b) molecular weight, (c) lipid solubility (and corresponding fat content of milk), (d) maternal plasma concentration, (e) drug half-life, and (f) drug pH. Low-molecular-weight drugs passively diffuse into breast milk, but larger molecules are not likely to transfer in large amounts. Colostrum is secreted in the first couple of days after birth and has high quantities of immunoglobulins, maternal lymphocytes, and maternal macrophages. While greater amounts of drugs are present in colostrum, the amount received by the nursing infant is minimal because of the limited volume of colostrum produced. A greater volume of mature milk is produced, but drug transfer into mature milk is lower because of tight cell-to-cell junctions. Weak bases are not ionized in the maternal circulation and easily transfer to breast milk. Likewise, drugs with longer half-lives are more likely to maintain higher levels in breast milk, resulting in greater exposure to the infant. Infant-related factors may also influence the amount of drug ingested through breastfeeding. Both the frequency of feedings and the amount of milk ingested are important considerations. Exclusively breastfed infants are more likely to ingest larger amounts of drugs than older infants who receive other foods. Strategies for reducing the risk to the infant include selection of medications that would be considered safe for use in the infant. Drugs with shorter half-lives accumulate less, and those that are more protein bound do not cross into breast milk as well as those that are less protein bound. Drugs with lower oral bioavailability and lower lipid solubility are good choices. During short-term drug therapy, the mother can pump and discard milk to preserve her milk-producing capability if the medication is not considered compatible with breastfeeding. All may be of assistance in determining safe and appropriate medications to use during breastfeeding. Mastitis 8 Mastitis is inflammation of the breast that occurs in 3% to 20% in lactating women. Signs and symptoms include breast tenderness, redness, warmth, flulike symptoms, and fever (temperature 101. Risk factors for developing mastitis include breast engorgement, plugged milk ducts, oversupply of milk, and cracked nipples. Affected women should be counseled to continue breastfeeding from both breasts throughout treatment and to pump if breasts are not emptied completely with feedings. Postpartum psychosis is more severe and can present as mania, psychotic depression, or schizophrenia but is rare, affecting less than 1% of new mothers; hospitalization is usually indicated. Psychotherapy, including interpersonal psychotherapy, cognitive behavioral therapy, and group/family therapy, has been shown effective for treatment of postpartum depression. In cases where pharmacotherapy is warranted, selection of medication with low transfer to breast milk is desirable. Methodological issues in the epidemiological study of the teratogenicity of drugs. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling (Final Rule). The management of nausea and vomiting of pregnancy and hyperemesis gravidarum-a 2013 update. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Pharmacologic management of asymptomatic bacteriuria and urinary tract infections in women. Fetal safety of drugs used in the treatment of allergic rhinitis: A critical review. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. American College of Obstetricians and Gynecologists; Committee on Practice Bulletins-Obstetrics. Tocolytic therapy for preterm delivery: Systematic review and network meta-analysis. Committee on Practice Bulletins-Obstetrics, the American College of Obstetricians and Gynecologists. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. The effect of adding a background infusion to patient-controlled epidural labor analgesia on labor, maternal, and neonatal outcomes: A systematic review and metaanalysis. The prevention and treatment of postpartum haemorrhage: What do we know, and where do we go to next The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Safety during breastfeeding: Drugs, foods, environmental chemicals, and maternal infections. The median menstrual cycle length is 28 days, but it can range from 21 to 40 days. Generally, variation in length is greatest in the follicular phase, particularly in the years immediately after menarche and before menopause. Patient-specific factors (eg, frequency of intercourse, age, smoking status, and concomitant diseases or medications) must be evaluated when selecting a contraceptive method. Adverse effects or difficulties using the chosen method should be monitored carefully and managed in consideration of patient-specific factors. Estradiol stops the menstrual flow from the previous cycle, thickening the endometrial lining of the uterus to prepare it for embryonic implantation.

Common symptoms of benzodiazepine withdrawal include anxiety symptoms 5 weeks into pregnancy mesalamine 800 mg on-line, insomnia medications via g-tube discount mesalamine 400 mg line, restlessness medications 4 less buy mesalamine 800 mg mastercard, muscle tension medications when pregnant trusted mesalamine 400 mg, and irritability medicine rising appalachia lyrics purchase mesalamine online now. Less frequently occurring symptoms are nausea, malaise, coryza, blurred vision, diaphoresis, nightmares, depression, hyperreflexia, and ataxia. Tinnitus, confusion, paranoid delusions, hallucinations, and seizures occur rarely. Withdrawal seizures can occur with both therapeutic and high doses of benzodiazepines with a short elimination halflife, usually within 3 days of drug discontinuation. They can occur approximately 1 week after discontinuation of agents with a long elimination half-life. High benzodiazepine doses, a long duration of therapy, and concurrent ingestion of drugs that lower the seizure threshold are risk factors for withdrawal seizures. The onset of withdrawal symptoms in patients ingesting benzodiazepines with short elimination half-lives occurs much earlier (within 24-48 hours) than in those taking benzodiazepines with long elimination half-lives (within 3-8 days). Other factors associated with an increased incidence and severity of benzodiazepine withdrawal include high doses and long-term benzodiazepine therapy. Slow drug taper is extremely important for the drugs with a short elimination half-life, because some individuals have greater difficulty with discontinuation. Withdrawal symptoms with short half-life benzodiazepines were no more severe than with longer half-life agents; therefore, switching from a short- to long-acting benzodiazepine before gradual taper is not supported. Although tolerance develops to the sedative, muscle relaxant, and anticonvulsant activities, the benzodiazepines do not appear to lose anxiolytic or antipanic efficacy. However, the anxiolytic efficacy of benzodiazepines in longterm clinical trials (greater than 6-8 months of chronic use) has not been documented. Concurrent use of medications that inhibit cytochrome P450 3A4 (eg, ketoconazole, nefazodone, and ritonavir) can increase the blood levels of alprazolam and diazepam. Dosing and Administration Benzodiazepine dosage requirements vary widely among patients and must be individualized. Three to 4 weeks of a daily dose at the maximum dose constitutes an adequate clinical trial (see Table 70-4). In general, benzodiazepines should be used with a regular dosing regimen and not on an as-needed basis. Patients should understand that benzodiazepines provide symptomatic relief but do not solve underlying psychological problems. Patients should be instructed not to decrease or discontinue benzodiazepine usage without contacting their prescriber. There is evidence that maternal anxiety during pregnancy and the postpartum period potentially pose significant risk to the child. Clinical practice guidelines for anxiety disorders recommend use of fluoxetine, sertraline, or citalopram; however, jitteriness, myoclonus, and irritability in the neonate and premature infant have been reported. Clinicians should avoid benzodiazepine use during the first trimester, use the lowest dosage for the shortest period of time, divide the total daily dosage into two or three doses to prevent high peak plasma levels, and use the agent as monotherapy. Should benzodiazepines be required during pregnancy, the preferred agents are diazepam and chlordiazepoxide. Diazepam and clonazepam should not be used in nursing mothers because infants can experience sedation, lethargy, and weight loss. Increased monitoring for behavioral changes with benzodiazepines and suicide-related adverse effects with antidepressants is necessary if these agents are prescribed. Patients with hepatic disease are at risk for drug accumulation and subsequent complications. Therefore, intermediate- or short-acting benzodiazepines without active metabolites are preferred for chronic use. Drug Interactions Drugs that inhibit cytochrome P450 3A4 (eg, verapamil, itraconazole, fluvoxamine) can increase buspirone levels. It is not useful in clinical situations requiring immediate anxiolysis or for situations requiring as-needed anxiolytic therapy. The patient should be assessed for response to or intolerance of previous treatment approaches. The patient should be an integral part of decision making and should be informed about effectiveness, common adverse effects, duration of treatment, cost associated with treatment, and what to expect when treatment is discontinued. Ideally, the patient should have no or minimal anxiety or depressive symptoms and no functional impairment. At any point of nonresponse or loss of previous response, the clinician should assess for (a) symptoms (eg, psychotic symptoms) that may suggest a need for additional medications or (b) reasons for treatment nonadherence (eg, adverse effects, cost of medications, limited understanding of the illness or treatments). Once a patient has responded to pharmacotherapy, the regimen should be continued for at least 1 year. Alprazolam, clonazepam, fluoxetine, paroxetine, sertraline, and venlafaxine are approved for this indication. Because of the risk of dependency, benzodiazepines should be used only after several trials of antidepressants have failed. In patients whose illness is complicated by a history of alcohol or drug abuse, benzodiazepine use should be avoided. Patients should be free of panic attacks, have no or minimal anticipatory anxiety and agoraphobic avoidance, and have no functional impairment. With all effective drug therapies, resolution of agoraphobic avoidance tends to occur slowly. Imipramine effectively blocks panic attacks within at least 4 weeks; however, maximal improvement (including antiphobic response) does not occur until 8 to 12 weeks. Up to 40% of patients experience stimulant-like effects, including anxiety, insomnia, and jitteriness. Dosing and Administration When using imipramine, treatment should be slowly increased by 10 mg every 2 to 4 days as tolerated (Table 70-8). Increasing the dose to 150 mg/day after initial nonresponse or partial response is recommended. Relapse rates of 50% or higher are common despite slow drug tapering during discontinuation of therapy. Dosing and Administration Doses of clonazepam can be increased rior to placebo in the proportion of patients becoming free from fullsymptom panic attacks. Other data support efficacy of venlafaxine in reducing the severity of anticipatory anxiety, fear, and avoidance. The duration of action of immediate-release alprazolam can be as little as 4 to 6 hours with resulting breakthrough symptoms; use of the extended-release alprazolam or clonazepam will avoid this problem. Most patients require 3 to 6 mg/day of alprazolam, and some need higher doses to obtain a full therapeutic (antipanic and antiphobic) response. Therapy should be altered if there is no response after 6 to 8 weeks of an adequate dose. The duration of the acute phase with benzodiazepines is approximately 1 month because response is rapid. A regular dosing schedule rather than an "as-needed" schedule is preferred for patients with panic disorder who are taking benzodiazepines, where the goal is to prevent panic attacks rather than reduce symptoms once an attack has already occurred. The most important determinant of adherence with maintenance therapy is the tolerability of adverse events. The primary risk of long-term benzodiazepine use is the development of dependence and withdrawal symptoms upon discontinuation. Abuse of benzodiazepines usually is confined to patients with a personal or family history of substance or alcohol abuse. Benzodiazepines should be tapered over 2 to 4 months at rates no higher than 10% of the dose per week. There is an ongoing controversy about the long-term use of benzodiazepines in the treatment of anxiety and related disorders. Most treatment guidelines recommend that use of benzodiazepines be limited to short-term use because of the risk for tolerance, dose escalation, dependence, and potential abuse. In addition, recent data highlight a potential increased 1093 Special Populations Elderly patients with panic disorder have fewer, less intense symptoms and avoidant behavior than younger patients. Limited data suggest that the course of panic disorder is highly variable during pregnancy and the postpartum period. It is unclear whether uncontrolled symptoms of panic disorder affect the course or outcome of pregnancy. Nonpharmacologic interventions should be considered as first-line treatment in these patients. Pharmacotherapy may also be indicated but requires careful evaluation of the potential benefits and risks. Treatment outcomes can be assessed objectively by use of the Panic Disorder Severity Scale. Remission is defined as equal to or less than 3 with no or mild agoraphobic avoidance, anxiety, disability, or depressive symptoms. During drug discontinuation, the frequency of appointments should be increased to evaluate for emergence of potential withdrawal symptoms and monitor for relapse. Evaluation of these factors in patients with genetic alterations in metabolism is an important part of personalized therapy. The most recent data available regarding research on the effects of pharmacogenetic properties of the benzodiazepines can be located online at the Pharmacogenomics Knowledgebase. Providing education about the disorder may relieve some of the symptoms of panic by helping the patient to realize that the symptoms are neither life-threatening nor uncommon. Patients should be informed regarding the lag time before a therapeutic response will occur and any problematic side effects that might affect early adherence (eg, jitteriness syndrome). Many patients are reluctant to take drugs for fear that their illness will worsen or that they will become addicted. Adverse events are often perceived as a worsening of the illness and can contribute to nonadherence or prevent necessary dosage increases. A strong therapeutic alliance between the clinician and the patient is important in supporting the patient through the aspects of the treatment that may provoke anxiety. Desired Outcomes the goals of therapy in the acute phase of treatment are to reduce physiologic symptoms of anxiety (eg, tachycardia, flushing, and sweating), social anxiety, and phobic avoidance. Although the primary goal of treatment is to reduce anxiety symptoms to manageable levels, even modest reductions in avoidance and discomfort can be highly valued by patients. Therefore, it is important to set reasonable expectations for response to therapy. Consideration of current symptoms, prior treatments, concurrent conditions, and history of substance abuse guide treatment selection. The only significant indication of treatment response in pharmacotherapy is duration of treatment. Evaluation of Therapeutic Outcomes During the first few weeks of the acute phase of therapy, patients with panic disorder should be seen every 1 to 2 weeks when starting a new medication, and then every 2 to 4 weeks to adjust drug dosages based on improvement in panic symptoms and to monitor for adverse events. Selfhelp group programs that focus on effective communication can benefit people with anxiety involving public speaking. The onset of effect was delayed 4 to 8 weeks, and maximum benefit was often not observed until 12 weeks or longer. Large relapse prevention trials with escitalopram, paroxetine, and sertraline demonstrated relapse rates of 4% to 14% with continued drug treatment, compared with 36% to 39% with placebo. Increase the dose as tolerated in patients who have not responded after 4 weeks of therapy. Venlafaxine Efficacy the efficacy of venlafaxine extended-release was estab- lished in four double-blind, parallel-group, 12-week, multicenter, placebo-controlled, flexible-dose studies and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study. Dosing and Administration Additional therapeutic benefits of venlafaxine extended-release above 75 mg/day were not shown. Treatment Resistance 9 An adequate antidepressant trial usually consists of 8 to 12 weeks (at maximum dosages). There are little data on the choice of treatments if there is a partial response to antidepressants therapy. Quetiapine monotherapy showed a large effect size on the Social Phobia Inventory when compared with placebo. If a patient is switched from another antidepressant to phenelzine, an appropriate washout period should be followed. Alternative Agents Benzodiazepines Benzodiazepines are commonly used in the treatment of patients who cannot tolerate or fail to respond to antidepressants. Patients should be instructed not to decrease or discontinue clonazepam without consulting their clinician because of the risks of rebound anxiety and withdrawal symptoms. If the disorder is not treated, it can persist into adulthood and increase the risk of depression and substance abuse. Headache, nausea, drowsiness, insomnia, jitteriness, and stomachaches were reported in children receiving antidepressants. The adverse effects of benzodiazepines in children include drowsiness, oppositional behavior, disinhibition, and fatigue. Often the symptoms that patients desire to relieve interfere with the ability to seek treatment. It is important to develop an alliance with the patient and offer reassurance throughout the treatment process. Comorbid depression or suicidal ideation requires careful evaluation and close monitoring. Patients with comorbid substance abuse on presentation may require postponing pharmacotherapy until after detoxification and avoidance of use of benzodiazepines as part of treatment. Patients should be instructed about the gradual onset of effect, when to expect full therapeutic benefit, and that long-term therapy is required. When drug therapy is discontinued, the dosage needs to be gradually decreased over several months, and the patient should be seen more frequently to monitor for signs and symptoms of relapse or withdrawal. It is important to remember that although pharmacotherapy usually leads to improvement in social and occupational functioning, most patients do not achieve a full remission.

A solution that is stable for 72 hours at room temperature can be prepared by adding 10 crushed tablets of carbidopa/l-dopa 10/100 (or 25/100) mg and 2 g crystalline ascorbic acid to 1 L of water treatment plan for anxiety discount mesalamine 800 mg without a prescription. Therefore symptoms 0f gallbladder problems proven 800 mg mesalamine, engaging and supporting patients and caregivers in overcoming barriers to medication adherence is important medicine river animal hospital order mesalamine line. Remedies for early morning dystonia include bedtime administration of a long-acting dopamine agonist symptoms when quitting smoking discount mesalamine 800 mg buy on-line, long-acting carbidopa/l-dopa medications quinapril trusted mesalamine 800 mg, or baclofen. Additionally, focal injections of botulinum toxin type A or B are effective for persistent focal dystonias. Focal dystonias can also occur as l-dopa peak dose effect and management is similar to that of dyskinesias. A common concern with use of these agents is the potential for interactions with drugs that possess serotonergic activity. However, concomitant use of serotonergic antidepressants is not contraindicated, and these drugs can be used concomitantly when clinically warranted. Adverse effects of selegiline are minimal but can include agitation, insomnia (especially if administered at bedtime), hallucinations, and orthostatic hypotension (see Table 59-4). Selegiline also increases the peak effects of l-dopa and can worsen preexisting dyskinesias or psychiatric symptoms such as delusions. Hence, bioavailability is improved and formation of amphetamine metabolites is reduced. For the management of motor fluctuations, the efficacy of rasagiline appears similar to that of entacapone, offering approximately 1 hour of extra on time during the day. Consequently, when an adjunctive agent is required for managing motor fluctuations, rasagiline is considered a first-line agent (as is entacapone). Additionally, subcutaneously administered apomorphine may be used as rescue therapy for delayedon or no-on periods. A drug-free period ("drug holiday") may be initiated in an attempt to modify postsynaptic dopamine receptors and thus decrease unpredictable off states. Although not commonly performed because of discomfort (to the patient) and medical risks, when drug holidays are performed, it should be under close medical supervision. Patients may report that their "feet suddenly feel stuck to the floor" during ambulation or that they have difficulty initiating steps (start hesitation) or turns (turn hesitation). Freezing often is exacerbated by anxiety or when perceived obstacles (eg, doorways, turnstiles) are encountered. Management consists of physical therapy along with use of assistive walking devices and sensory cues. Freezing "Freezing," or a sudden, episodic akinesia of the lower 9 Dyskinesias Another complication of l-dopa therapy is "on" period dyskinesias (involuntary choreiform movements involving usually the neck, trunk, and lower/upper extremities). Among all the antiparkinson medications, dyskinesias are specific to l-dopa therapy. If patients report "shakiness," it is important to clarify if they are referring to tremor or dyskinesias. Dyskinesias usually are associated with peak striatal dopamine levels (peak-dose dyskinesia) and, simplistically, can be thought of as too much movement secondary to extension of the l-dopa pharmacologic effect. Lowering the dose of carbidopa/l-dopa to counteract dyskinesias should be attempted. However, the use of a lower dose may result in suboptimal control of parkinsonian features, thus, necessitating addition of another antiparkinson agent (eg, dopamine agonist). For severe dyskinesias (despite pharmacologically optimized therapy), surgery should be considered. Dystonias often occur in the early morning hours (as a result of waning drug levels) and improve with the first carbidopa/l-dopa 905 Clinical Controversy. The traditional approach is to initiate symptomatic therapy when there is evidence of functional impairment. However, others believe that early treatment with a dopaminergic agent, in the absence of functional impairment, acts to alleviate stress on intrinsic compensatory mechanisms, and greater long-term benefit is derived. Randomized controlled studies designed to specifically address this approach have not been conducted, and there is insufficient information on whether treatment in the absence of functional impairment has an acceptable riskbenefit profile or whether this is cost-effective. Both reduce the peripheral conversion of l-dopa to dopamine, thus enhancing central l-dopa bioavailability. Its use is limited by reports of fatal hepatotoxicity, such that strict monitoring of hepatic function, especially during the first 6 months of therapy, is required (see Table 59-4). Because of the hepatotoxicity risk, tolcapone is reserved for patients with fluctuations that are not responding to other therapies. Entacapone has a shorter half-life than tolcapone, and 200 mg needs to be given with each dose of carbidopa/l-dopa up to a maximum of eight times per day. A triple-combination product of carbidopa/ l-dopa/entacapone offers convenience for some patients (ie, fewer tablets to administer). Entacapone is considered one of the first-line choices for adjunctive therapy to manage motor fluctuations. Patients should be advised that other adverse effects include brownish-orange urinary discoloration and delayed onset of diarrhea (weeks to months later). Dopamine Agonists Dopamine agonists fall into two pharmacologic subtypes: ergotderived agonists (bromocriptine) and the nonergot agonists (apomorphine, pramipexole, ropinirole, and rotigotine). For older patients, dopamine agonists should be used conservatively due to greater likelihood for development of intolerable side effects. For patients with cognitive problems or dementia, dopamine agonists should be avoided. Common adverse effects of dopamine agonists include nausea, confusion, drowsiness, hallucinations, lower-extremity edema, and orthostatic hypotension (see Table 59-4). When initiating therapy, a slow dose titration is required to minimize development of adverse effects, particularly nausea. The addition of a dopamine agonist to carbidopa/l-dopa therapy also can induce dyskinesias, especially in patients with preexisting dyskinesias. Less common but serious adverse effects include impulsive and compulsive behaviors (eg, pathologic gambling or shopping; paraphilia), delusions/psychosis, and sleep attacks (sudden, unexpected episodes of sleep). Hallucinations and delusion should be managed using a systematic approach that starts with dose reduction or discontinuation of the dopamine agonist, and if needed, addition of an atypical antipsychotic medication such as clozapine, pimavanserin, or quetiapine. Potent inhibitors (eg, fluoroquinolone antibiotics) and inducers (eg, cigarette smoking) of this enzyme likely will lead to alterations in ropinirole clearance. Rotigotine transdermal patch is initiated at 2 mg once daily and increased weekly by 2 mg increments to achieve desired therapeutic effect. The rotigotine transdermal patch provides continuous release of drug over a 24-hour period. Apomorphine is an aporphine alkaloid originally derived from morphine, but lacks narcotic properties. Upon subcutaneous administration, apomorphine produces an "on" response within 20 minutes. Sites of injection (abdomen, upper arm, and upper thigh) should be rotated to avoid development of subcutaneous nodules. Apomorphine elimination half-life is approximately 40 minutes, and the duration of benefit can be up to 100 minutes. Nausea and vomiting are common side effects, and prior to the initiation of apomorphine, patients should be premedicated with the antiemetic trimethobenzamide. Personalized therapy should take into account patient-specific factors including age; comorbidities; severity of functional impairment; nonmotor symptoms; patient preferences, therapeutic goals and outcomes; employment status; drug tolerability; presence of cognitive impairment or motor complications; need for skilled assistance; and health-related economics. The lowest dose of antiparkinson medication that provides satisfactory symptomatic results should be used, and for patients already on carbidopa/l-dopa, optimization of the regimen should be attempted before adding adjunctive agents. With the increasing motor disability, emergence of medication side effects, and changes in severity of nonmotor symptoms, therapy adjustments (eg, dose reductions, 906 medication addition or discontinuation) are expected, and desired therapeutic endpoints should be routinely reassessed. Dopamine agonist monotherapy provides greater symptomatic benefit for patients with mild to moderate impairment. For patients who are older, cognitively impaired, intolerant of dopamine agonists, or experiencing moderate or severe functional impairment, carbidopa/l-dopa is preferred. Ultimately, all patients will require the use of carbidopa/l-dopa (either as monotherapy or in combination with other agents). With the development of motor fluctuations, patients should administer carbiopa/l-dopa more frequently. For management of carbodopa/l-dopa­induced peakdose dyskinesias, a reduction in l-dopa dose and/or addition of amantadine should be considered. Surgery is considered only in patients who need more symptomatic control or who are experiencing severe motor complications despite pharmacologically optimized therapy. The treatment plan evolves as the disease progresses and must include consideration of short-term symptomatic relief as well as long-term effects. Patient and caregiver satisfaction is an important component of evaluating therapeutic outcomes. Additionally, some symptoms do not respond to pharmacotherapy (eg, freezing, gait, and postural instability). It is also important to be aware of and adhere to the general guidelines and recommendations for geriatric health maintenance and disease prevention (eg, bone health, routine vaccinations, and vitamin and mineral supplementations). Patients and caregivers can participate in treatment by recording medication administration times as well as the duration of on and off times that can be reviewed at each visit. For example, D2 blockers (such as metoclopramide and typical antipsychotics) can worsen motor features and should be avoided. If the patient reports memory problems, medications with anticholinergic properties should be avoided. Screening for anxiety or depressive disorders will help determine if antidepressant or antianxiety therapy is needed. If falling is a problem, it is important to investigate whether falls are secondary to insufficient motor control, orthostatic hypotension, or drug side effects, such as dizziness. The former may necessitate an increase in dose of antiparkinson agents, and the latter two conditions, a reduction in drug dosage. Physical therapy is also helpful for strengthening ambulation and balance skills to minimize falls. The patient should be questioned about any difficulties with their antiparkinson medications, including presence of adverse effects. With the changes in pharmacotherapy (eg, drug addition, discontinuation, dose change), follow-up monitoring for efficacy and side effects should occur within 1 or 2 weeks and may occur via telephone. Educate the patient that immediate-release carbidopa/l-dopa is absorbed best on an empty stomach but is commonly taken with food to minimize nausea. Avoid administration of conventional selegiline in the late afternoon or evening to minimize insomnia. Monitor to ensure that the patient and/or caregivers understand the prescribed medication regimen. For example, they should understand that catechol-O-methyltransferase inhibitors work by enhancing the effect of l-dopa and that the patient should not discontinue medication without notifying the clinician. Monitor and inquire specifically about dose-by-dose effects of medication, including response to doses of medication and the presence of dyskinesias, wearing-off effects, dizziness, nausea, orthostasis, or visual hallucinations. Offer suggestions to help alleviate these, or encourage the patient to discuss them with the clinician. Monitor caregiver involvement and facilitation for early detection of abnormal behaviors, dyskinesias, falls, hallucinations, impulsivity, memory problems, mood changes, and sleep disorders. Monitor for nonadherence and, if present, inquire for possible reasons (eg, dosing convenience, financial issues, and adverse effects) and offer suggestions. Monitor for presence of drugs that can exacerbate idiopathic Parkinson disease motor features (eg, D2 receptor blockers). Evaluate whether the presence of an anticholinergic agent is causing confusion or cognitive impairment. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with -synucleinopathies. Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use. Patients taking analgesics should be monitored for response and side effects, particularly respiratory depression, sedation and constipation associated with opioids. Oral analgesics are preferred over other dosage forms whenever feasible, but it is important to adjust the route of administration to the needs of the patient. Equianalgesic doses are useful as a guide when converting from one agent to another, but further dose titration usually is required to achieve treatment goals. Doses must be individualized for each patient and administered for an adequate duration of time. As needed regimens should be used for breakthrough pain or when acute pain displays wide variability and/or has subsided greatly. For chronic pain that has a maladaptive inflammatory and/or neuropathic component, anticonvulsants, topical analgesics, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and opioids should be considered based on evidence based recommendations when available. Whenever possible, a multidisciplinary approach and nonpharmacologic strategies should be used. It can be physiologic and protective (adaptive) or pathophysiologic and harmful (maladaptive). Pain that occurs as a result of unavoidable tissue damage (trauma or surgery) creates sensitization at and adjacent to the site of tissue injury. The physiological processing of pain occurs within a neurotransmission circuit via a number of steps known as transduction, conduction, transmission, perception, and modulation. Understanding the pathophysiology of pain and maintaining a thorough understanding of both pharmacologic and nonpharmacologic treatment modalities are important factors in addressing pain control.

Mesalamine 400 mg order free shipping. How To Get Rid Of Headache Causes Symptoms & Treatment In Bangla | Tutorial Video.

References

• Flynn MR, Barrett C, Cosio FG, et al: The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J 2005;26:308-313.
• Cumming MJ, Hall AJ, Burbridge BE: Psoas muscle hematoma secondary to a ruptured abdominal aortic aneurysm: case report, Can Assoc Radiol J 51:279-280, 2000.
• Conway SP, Etherington C, Munday J, et al. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother. 2000;34(11): 1238-1242.
• Horner PJ, Blee K, Falk L, et al: 2016 European guidelines on the management of non-gonococcal urethritis, Int J STD AIDS 27(11):928n937, 2016.
• Miao R, Li J, Sun Z, et al. Association between the CD209 promoter -336A/G polymorphism and susceptibility to tuberculosis: a meta-analysis. Respirology 2012; 17: 847-853.
• Jander S, Bischoff J, Woodcock BG. Plasmapheresis in the treatment of Amanita phalloides poisoning: II. A review and recommendations. Ther Apher. 2000;4(4):308-312.